Prudential Financial Inc. Trims Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Prudential Financial Inc. reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 17.5% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 125,985 shares of the medical equipment provider's stock after selling 26,661 shares during the period. Prudential Financial Inc. owned approximately 0.06% of Hologic worth $9,082,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. General Partner Inc. acquired a new stake in Hologic during the fourth quarter worth about $26,000. Venturi Wealth Management LLC grew its stake in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after purchasing an additional 261 shares during the period. EverSource Wealth Advisors LLC increased its holdings in shares of Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 260 shares in the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after purchasing an additional 159 shares during the period. Finally, Smithfield Trust Co boosted its holdings in Hologic by 160.0% during the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after buying an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Remove Ads

Hologic Price Performance

HOLX stock traded down $0.55 during mid-day trading on Thursday, reaching $60.02. The company's stock had a trading volume of 346,660 shares, compared to its average volume of 1,805,241. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company's 50 day moving average is $64.69 and its two-hundred day moving average is $72.88. Hologic, Inc. has a fifty-two week low of $58.38 and a fifty-two week high of $84.67. The stock has a market cap of $13.47 billion, a PE ratio of 18.93, a P/E/G ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on HOLX. Wolfe Research began coverage on shares of Hologic in a report on Friday, December 13th. They issued a "peer perform" rating for the company. Needham & Company LLC cut Hologic from a "buy" rating to a "hold" rating and set a $90.00 price target for the company. in a report on Monday, February 3rd. Argus downgraded Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Leerink Partners cut Hologic from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. Finally, William Blair reiterated an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.